These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9814868)

  • 21. Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children.
    Horneff G; Adams O; Wahn V
    AIDS; 1998 Mar; 12(5):489-94. PubMed ID: 9543447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
    Friedland GH; Pollard R; Griffith B; Hughes M; Morse G; Bassett R; Freimuth W; Demeter L; Connick E; Nevin T; Hirsch M; Fischl M
    J Acquir Immune Defic Syndr; 1999 Aug; 21(4):281-92. PubMed ID: 10428106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease.
    Piketty C; Castiel P; Belec L; Batisse D; Si Mohamed A; Gilquin J; Gonzalez-Canali G; Jayle D; Karmochkine M; Weiss L; Aboulker JP; Kazatchkine MD
    AIDS; 1998 May; 12(7):745-50. PubMed ID: 9619806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
    Vidal C; García F; Gatell JM; Leal M; Clotet B; Pumarola T; Miró JM; Mallolas J; Ruiz L; Cruceta A; Tortajada C
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):55-60. PubMed ID: 9732070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency.
    Thuret I; Michel G; Chambost H; Tamalet C; Giraud P; Brunet C; Perrimond H
    AIDS; 1999 Jan; 13(1):81-7. PubMed ID: 10207548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
    Kline MW; Fletcher CV; Harris AT; Evans KD; Brundage RC; Remmel RP; Calles NR; Kirkpatrick SB; Simon C
    J Pediatr; 1998 Mar; 132(3 Pt 1):543-6. PubMed ID: 9544920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group.
    Reynes J; Denisi R; Massip P; Izopet J; Pellegrin I; Segondy M
    J Acquir Immune Defic Syndr; 1999 Sep; 22(1):103-5. PubMed ID: 10534154
    [No Abstract]   [Full Text] [Related]  

  • 29. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
    Japour AJ; Lertora JJ; Meehan PM; Erice A; Connor JD; Griffith BP; Clax PA; Holden-Wiltse J; Hussey S; Walesky M; Cooney E; Pollard R; Timpone J; McLaren C; Johanneson N; Wood K; Booth D; Bassiakos Y; Crumpacker CS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):235-46. PubMed ID: 8898668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy.
    Bouscarat F; Levacher M; Landman R; Muffat-Joly M; Girard PM; Saimot AG; Brun-Vézinet F; Sinet M
    AIDS; 1998 Jul; 12(11):1267-73. PubMed ID: 9708405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
    Henry K; Erice A; Tierney C; Balfour HH; Fischl MA; Kmack A; Liou SH; Kenton A; Hirsch MS; Phair J; Martinez A; Kahn JO
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):339-49. PubMed ID: 9833742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.
    Tamalet C; Lafeuillade A; Fantini J; Poggi C; Yahi N
    AIDS; 1997 Jun; 11(7):895-901. PubMed ID: 9189215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
    Katzenstein DA; Hammer SM; Hughes MD; Gundacker H; Jackson JB; Fiscus S; Rasheed S; Elbeik T; Reichman R; Japour A; Merigan TC; Hirsch MS
    N Engl J Med; 1996 Oct; 335(15):1091-8. PubMed ID: 8813039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients.
    Gallant JE; Chaisson RE; Keruly JC; Moore RD
    AIDS; 1999 Feb; 13(2):225-9. PubMed ID: 10202828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.
    Lafeuillade A; Tamalet C; Poggi C; Pellegrino P; Tourres C; Izopet J
    AIDS; 1997 Jan; 11(1):67-72. PubMed ID: 9110077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
    Mauss S; Adams O; Willers R; Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):469-77. PubMed ID: 8605592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
    Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
    N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
    Pakker NG; Kroon ED; Roos MT; Otto SA; Hall D; Wit FW; Hamann D; van der Ende ME; Claessen FA; Kauffmann RH; Koopmans PP; Kroon FP; ten Napel CH; Sprenger HG; Weigel HM; Montaner JS; Lange JM; Reiss P; Schellekens PT; Miedema F
    AIDS; 1999 Feb; 13(2):203-12. PubMed ID: 10202826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
    Raboud JM; Montaner JS; Conway B; Rae S; Reiss P; Vella S; Cooper D; Lange J; Harris M; Wainberg MA; Robinson P; Myers M; Hall D
    AIDS; 1998 Sep; 12(13):1619-24. PubMed ID: 9764780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.